[ad_1]
AstraZeneca has already started production of the UK government’s initial order for 30 million doses of its coronavirus vaccine, which has been developed in collaboration with researchers at the University of Oxford.
The vaccine has not been approved for use and is still being tested in the UK, Brazil and South Africa. However, last month, Professor Andrew Pollard, director of the Oxford Vaccine Group, said it is “possible” that there is enough clinical trial data on the Covid-19 vaccine from the University of Oxford to present to regulators this time. year.
The vaccine is delivered via a chimpanzee virus, called a vaccine vector, which contains the genetic code for the protein spikes found in the coronavirus. They are expected to elicit a strong immune response.
Health Secretary Matt Hancock told LBC that production of the UK batch of AstraZeneca vaccines had already started, long before approval was granted. He said:
“We already have 30 million doses contracted with AstraZeneca, in fact, they are already starting to manufacture those doses, before approval, so in case the approval comes, and it is still not sure, but it is improving, in case approval is obtained, then we are ready to implement.
“The best scenario is for it to happen this year. I think the first part of next year is most likely; the first few months of next year is most likely.”
“But we also bought vaccines before they were approved from a completely different series of international vaccines.”
[ad_2]
